[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577212":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":30,"collaborators":34,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":19,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":45,"enrollmentInfo":46,"targetDuration":19,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":59,"whyStopped":19,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":19},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"incretin mimetic discontinuation","EXPERIMENTAL","This study will enroll people who are taking an injectable weight loss drug, have lost weight with the help of this drug, and are required by their health insurance plan to discontinue treatment. They will be studied right before their medication runs out, and 3 months later",[13],"Other: discontinuation of weight loss medication",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"discontinuation of weight loss medication","Participants will be studied right before their injectable weight loss medication runs out, and 3 months later",[9],null,[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Roland James","CONTACT","414-955-6710","414-955-4992","rjames@mcw.edu",{"name":28,"role":23,"phone":24,"phoneExt":19,"email":29},"Lisa L Morselli, MD PhD","lmorselli@mcw.edu",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Lisa Morselli, MD PhD","Assistant Professor",[35],{"name":36,"class":6},"University of Wisconsin, Milwaukee","100577212","weight-changes-after-incretin-mimetics-100577212",false,"NCT06795360","Weight Changes After Incretin-mimetics","Inclusion Criteria:\n\n* adults 18 years or older\n* men and women\n* prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse\n* any ethnicity\n\nExclusion Criteria:\n\n* weight \\> or = 400 lb\n* type 1 or type 2 diabetes\n* patients taking steroid medications\n* anemia\n* heart disease\n* advanced kidney disease (CKD stage 4 and 5)\n* decompensated liver disease\n* hyperthyroidism\n* untreated hypothyroidism\n* active cancer\n* post solid organ or bone marrow transplant\n* HIV\u002FAIDS\n* pregnancy\u002Fplan for pregnancy in the next 6 months\n* breastfeeding\n* post-menopausal women\n* current smoker\n* current recreational drug use\n* night shift or rotating shift workers","ALL","18 Years","50 Years",{"count":47,"type":48},52,"ESTIMATED","INTERVENTIONAL",[51],"NA","The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?",[54],"Obesity and Obesity-related Medical Conditions",[56,57,58],"obesity","weight loss","weight gain","NOT_YET_RECRUITING","2026-02-20",{"date":62,"type":63},"2026-02-24","ACTUAL",{"date":65,"type":48},"2026-12-01",{"date":67,"type":48},"2031-11-30",{"name":5,"class":6}]